Rani El-Matbouli

For 34 years, we have been collaborating with global pharma and biotech partners to bring innovative therapies to patients in Central and Eastern Europe. Despite the region's challenging healthcare systems and complex yet promising markets, our team of 400 employees harnesses its expertise to ensure health equity in these underserved markets. Medis is a member of the World Orphan Drug Alliance (WODA) – a global alliance of full-service regional distributors for orphan and debilitating disease products. WODA covers 152 countries in the following regions: Central and Eastern Europe, Greater China, Israel, Greece, Malta, Cyprus, Latin America, the Middle East, North Africa & Turkey, Switzerland, Australia, New Zealand and South East Asia. Out-licensing: Become our commercialization partner and benefit from advanced, ready-to-launch consumer health products, which are already marketed in 20 countries and are further expanding. More information: www.medis.com/en/international-business/ Our business areas: • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners: • Direct local presence in 18 CEE countries • Full commercialization • Single point of contact and delivery • Strategic and localized market access approach • Highest compliance standards • Financial and credit excellence Major Partners: • Therapeutics: Bial – Biogen – Besins – HRA Pharma – Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics – Crown Aesthetics • Out-licensing partners: Ferrer – Pharmalink – Sarantis – Stada